ELISA-Based Crossmatching Allowing the Detection of Emerging Donor-Specific Anti-HLA Antibodies through the Use of Stored Donors’ Cell Lysates

Table 2

Results of different antibody detection and specification analyses in comparison with crossmatch-ELISA outcomes all of which exclude an involvement of anti-HLA DSA in a rejection episode of the 48-year-old heart recipient with high probability.

Serum sample	GTI screening	Luminex (SD)	AMS-ELISA-CM
	Class I/II ELISA	Class I/class II	Class I/class II
06/2010	neg./neg.	n.d./n.d.	n.d./n.d.
08/2010	neg./neg.	neg./neg.; (PRA = 0%)	neg./neg.
07/2011	neg./neg.	n.d./n.d.	n.d./n.d.
08/2012	neg./neg.	neg./neg.; (PRA = 0%)	n.d./n.d.
08/2013	neg./neg.	n.d./n.d.	n.d./n.d.
11/2014	neg./neg.	neg./neg.; (PRA = 0%)	n.d./n.d.
03/2015	neg./neg.	neg./neg.; (PRA = 0%)	neg./neg. (AbCr.)
For 03/2015 additionally:
LAT 1HD (anti-HLA class I Single Antigen ELISA): negative
LAT 1288 (anti-HLA class I/II Single Donor ELISA): negative

n.d.: not done; neg.: negative; pos.: positive; PRA%: panel-reactive antibodies %; SD: Single Donor/PRA resolution; analyses for entering the waiting list; analyses at the date of the transplantation; routinely performed posttransplantation analyses; analyses at the date of the clinically proven rejection episode; (AbCr.): after its discontinuation in 2013 the AMS-ELISA was replaced by the highly modified AbCross-ELISA.